Liuzosulfapyridine can control ankylosing spondylitis to some extent.
Ankylosing spondylitis is a chronic rheumatic disease mainly involving sacroiliac joints, spine and large joints of the limbs. Currently, the treatment is based on medication, and surgery is needed when necessary, and the medication broadly includes non-steroidal anti-inflammatory drugs (e.g., ibuprofen, etc.) and anti-rheumatic drugs (e.g., lancet sulfapyridine, thalidomide, etc.).
Sulfasalazine can improve joint pain, morning stiffness, and redness and swelling in ankylosing spondylitis patients, and it can reduce blood sedimentation, CRP and other laboratory activity indicators.
Common adverse drug reactions to salazosulfapyridine include abdominal pain, nausea, vomiting, etc. Liver and renal function and blood routine should be tested regularly while taking the drug. The drug is contraindicated for those who are allergic to sulfonamides, pregnant women, nursing mothers, and children under 2 years of age.
Sulfasalazine should be used under the guidance of a physician, and it is recommended that patients with ankylosing spondylitis go to the rheumatology and immunology department of a regular hospital for a detailed consultation, and follow the doctor’s instructions for standardized treatment.